Bora Pharmaceuticals CoTPE:6472 +1.74%87 ROE % is 9.15% as of Dec. 2025, which is 67% below its 10-year median of 27.39. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$716.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 933 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 89.39% on this metric.
The historical rank and industry rank for Bora Pharmaceuticals Co's ROE % or its related term are showing as below:
TPE:6472'
s ROE % Range Over the Past 10 Years
Min: 2.57 Med: 27.39 Max: 45.74
Current: 22.29
During the past 13 years, Bora Pharmaceuticals Co's highest ROE % was 45.74%. The lowest was 2.57%. And the median was 27.39%.
TPE:6472's ROE % is ranked better than 89.39% of 933
companies
in the Drug Manufacturers industry
Industry Median: 6
vs TPE:6472: 22.29
Bora Pharmaceuticals Co (TPE:6472) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's ROE % distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Bora Pharmaceuticals Co (TPE:6472) has a ROE % of 9.15% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bora Pharmaceuticals Co and its competitors. This is 67% below median its historical median of 27.39. Over the past decade, Bora Pharmaceuticals Co's ROE % has ranged from 2.57 to 45.74. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #99 out of 933 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is Bora Pharmaceuticals Co's ROE % too high?
Bora Pharmaceuticals Co's current ROE % of 9.15% is 67% below median its 10-year median of 27.39. Over the past 10 years, this metric has ranged from a low of 2.57 to a high of 45.74. The Drug Manufacturers industry median ROE % is 6.00. Bora Pharmaceuticals Co's value of 9.15% is 52.5% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #99 out of 933 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #99 out of 933 companies for ROE %. This places Bora Pharmaceuticals Co in the top 11% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Bora Pharmaceuticals Co's value of 9.15% is 52.5% above this benchmark. Historically, Bora Pharmaceuticals Co's own ROE % has ranged from 2.57 to 45.74 over the past decade. While the company's 10-year median is 27.39 vs. the industry median of 6.00, Bora Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current ROE % of 9.15% is 52.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current ROE % is 9.15%, which is 67% below median its own 10-year median of 27.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$716.94, compared to a current price of NT$439.50 — trading 38.7% below its estimated fair value. The current ROE % is 9.15%, which is 67% below median its 10-year median of 27.39 and 52.5% above the Drug Manufacturers industry median of 6.00. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current ROE % is 9.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$439.50 is trading 38.7% below its estimated GF Value™ of NT$716.94.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
ROE %: 9.15% (67% below median its 10-year median of 27.39)
GF Value™: NT$716.94 vs. price of NT$439.50 (38.7% below fair value)
Industry Position: 52.5% above the Drug Manufacturers median (#99 of 933)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
